PriceTargets.com logo

Aduro Biotech - ADRO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/31/1969 06:45 PM ET
+0 (0.00%)
Get New Aduro Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADRO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Aduro Biotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ADRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aduro Biotech. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2020HC WainwrightReiterated RatingBuy$3.75High
6/5/2020OppenheimerInitiated CoverageHoldHigh
6/2/2020HC WainwrightBoost TargetBuy$3.75 ➝ $4.00Low
5/4/2020OppenheimerReiterated RatingHoldHigh
1/31/2020SVB LeerinkBoost TargetOutperform$3.00 ➝ $7.00High
1/9/2020CowenDowngradeOutperform ➝ Market PerformHigh
12/18/2019HC WainwrightLower TargetBuy$7.00 ➝ $4.00High
12/18/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/2/2019CowenReiterated RatingBuyHigh
6/3/2019CIBCReiterated RatingOutperform ➝ Market PerformHigh
6/3/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/8/2019CowenReiterated RatingBuyHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aduro Biotech logo
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $10.93
Low: $2.28
High: $14.60

52 Week Range

Now: N/A

Volume

171,500 shs

Average Volume

162,237 shs

Market Capitalization

$236.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Aduro Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Aduro Biotech in the last twelve months:
View the latest analyst ratings for ADRO.

What is the current price target for Aduro Biotech?

0 Wall Street analysts have set twelve-month price targets for Aduro Biotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aduro Biotech in the next year.
View the latest price targets for ADRO.

What is the current consensus analyst rating for Aduro Biotech?

Aduro Biotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADRO.

What other companies compete with Aduro Biotech?

Other companies that are similar to Aduro Biotech include 2seventy bio, AC Immune, 23andMe, Aldeyra Therapeutics and Verastem. Learn More about companies similar to Aduro Biotech.

How do I contact Aduro Biotech's investor relations team?

Aduro Biotech's physical mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company's listed phone number is (206) 485-7051 and its investor relations email address is [email protected]. The official website for Aduro Biotech is www.aduro.com. Learn More about contacing Aduro Biotech investor relations.